C
Corrine Zarwan
Researcher at Lahey Hospital & Medical Center
Publications - 32
Citations - 1066
Corrine Zarwan is an academic researcher from Lahey Hospital & Medical Center. The author has contributed to research in topics: Internal medicine & Ovarian cancer. The author has an hindex of 10, co-authored 26 publications receiving 764 citations. Previous affiliations of Corrine Zarwan include Harvard University & Beth Israel Deaconess Medical Center.
Papers
More filters
Journal ArticleDOI
Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer
Ursula A. Matulonis,Suzanne Berlin,Percy Ivy,Karin Tyburski,Carolyn N. Krasner,Corrine Zarwan,Anna Berkenblit,Susana M. Campos,Neil S. Horowitz,Stephen A. Cannistra,Hang Lee,Julie Lee,Maria Roche,Margaret Hill,Christin Whalen,L. Sullivan,Chau Tran,Benjamin D. Humphreys,Richard T. Penson +18 more
TL;DR: Cediranib has activity in recurrent EOC, tubal cancer, and peritoneal cancer with predictable toxicities observed with other TKIs, and the primary end point was clinical benefit rate.
Journal ArticleDOI
Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer.
Shaveta Vinayak,Shaveta Vinayak,Sara M. Tolaney,Lee S. Schwartzberg,Monica M. Mita,Georgia A. McCann,Antoinette R. Tan,Andrea E. Wahner-Hendrickson,Andres Forero,Carey K. Anders,Gerburg M. Wulf,Patrick M. Dillon,Filipa Lynce,Corrine Zarwan,John K. Erban,Yinghui Zhou,Nathan Buerstatte,Julie R. Graham,Sujata Arora,Bruce J. Dezube,Melinda L. Telli +20 more
TL;DR: Combination niraparib plus pembrolizumab provides promising antitumor activity in patients with advanced or metastatic TNBC, with numerically higher response rates in those with tumor BRCA mutations.
Journal ArticleDOI
Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial
Christophe Le Tourneau,Christophe Le Tourneau,Christopher J. Hoimes,Corrine Zarwan,Deborah J. Wong,Sebastian Bauer,Rainer Claus,Rainer Claus,Martin Wermke,Subramanian Hariharan,Anja von Heydebreck,Vijay Kasturi,Vikram Chand,James L. Gulley +13 more
TL;DR: Avelumab showed clinical activity and a manageable safety profile in patients with platinum-treated mACC, and was well tolerated in both evaluable and evaluable patients with PD-L1+ tumors.
Journal ArticleDOI
TOPACIO/Keynote-162: Niraparib + pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial.
Shaveta Vinayak,Sara M. Tolaney,Lee S. Schwartzberg,Monica M. Mita,Georgia A. McCann,Antoinette R. Tan,Andrea E. Wahner Hendrickson,Andres Forero-Torres,Carey K. Anders,Gerburg M. Wulf,Patrick M. Dillon,Filipa Lynce,Corrine Zarwan,John K. Erban,Bruce J. Dezube,Yinghui Zhou,Nathan Buerstatte,Sujata Arora,Haroun Achour,Melinda L. Telli +19 more
TL;DR: TOPACIO (NCT02657889) is a fully enrolled study evaluating the safety and efficacy of combination treatment with selective PARP1/2 inhibitor niraparib + pembro in pts with met TNBC.
Journal ArticleDOI
Selective Blockade of Matrix Metalloprotease-14 with a Monoclonal Antibody Abrogates Invasion, Angiogenesis, and Tumor Growth in Ovarian Cancer
Rajani Kaimal,Raid Aljumaily,Sarah L. Tressel,Rutika V. Pradhan,Lidija Covic,Athan Kuliopulos,Corrine Zarwan,Young B. Kim,Sheida Sharifi,Anika Agarwal +9 more
TL;DR: Two studies provide a preclinical proof-of-concept for MMP-14 targeting as an adjuvant treatment strategy for advanced ovarian cancer by inhibiting the migratory and invasive properties of aggressive ovarian cancer cells in vitro.